Sagitta Biotech
Developer of a non-replicating active virosome platform for vaccines, targeted oncology immunotherapies, and gene therapies. The platform is designed to express foreign proteins on vector surfaces and deliver self-replicating RNA payloads (up to 17 kb) into target cells. The company emphasizes modular vector engineering for rapid design, compatibility with existing vaccine manufacturing processes, and collaboration/co-development with biotech and pharma partners.
Industries
N/A
Products
Tetravalent influenza vaccine (under development)
A multivalent vaccine candidate intended to target multiple influenza strains using the active virosome platform; stated as a proof-of-concept program under development.
Tetravalent influenza vaccine (under development)
A multivalent vaccine candidate intended to target multiple influenza strains using the active virosome platform; stated as a proof-of-concept program under development.
Services
Platform co-development and subcontracting
Collaborative development and technology access for custom vaccines, oncology, and gene therapy programs using the active virosome platform.
Platform co-development and subcontracting
Collaborative development and technology access for custom vaccines, oncology, and gene therapy programs using the active virosome platform.
Expertise Areas
- Viral vector engineering
- Vaccine development (multivalent)
- Oncology-targeted immunotherapy
- Gene therapy vector development
Key Technologies
- Non-replicating virosome (viral-derived) vectors
- Self-amplifying (self-replicating) RNA
- Surface antigen display / receptor engineering
- Modular cassette cloning system